Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-06-18

Clinical Trial Update: A Phase 2 Study to Evaluate AL001 in C9orf72-Associated ALS [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating AL001 in C9orf72-associated amyotrophic lateral sclerosis has been terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • AL001

Snippet

Sponsor: Alector Inc. | Conditions: Amyotrophic Lateral Sclerosis | Phase 2 | Status: TERMINATED | Results posted: 2025-06-18